Frequency of all Adverse Events 6 years [clinicaltrials_resource:576143a2fea19029cecccec3790efd4e]

Frequency of all Adverse Events 6 years [clinicaltrials_resource:576143a2fea19029cecccec3790efd4e]

750mg Intravenous, monthly and individual dosing schedule
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:576143a2fea19029cecccec3790efd4e
Open-Label Extension Of Intravenous Mepolizumab In Patients With Hypereosinophilic Syndrome [clinicaltrials:NCT00097370]
clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Frequency of all Adverse Events 6 years [clinicaltrials_resource:576143a2fea19029cecccec3790efd4e]

750mg Intravenous, monthly and individual dosing schedule
clinicaltrials resource [clinicaltrials_vocabulary:Resource]
Secondary outcome [clinicaltrials_vocabulary:secondary-outcome]
http://bio2rdf.org/clinicaltrials_resource:576143a2fea19029cecccec3790efd4e
Bio2RDF identifier
576143a2fea19029cecccec3790efd4e
Bio2RDF namespace
Bio2RDF uri
http://bio2rdf.org/clinicaltrials_resource:576143a2fea19029cecccec3790efd4e
measure [clinicaltrials_vocabulary:measure]
Frequency of all Adverse Events
time frame [clinicaltrials_vocabulary:time-frame]
description
750mg Intravenous, monthly and individual dosing schedule
identifier
clinicaltrials_resource:576143a2fea19029cecccec3790efd4e
title
Frequency of all Adverse Events 6 years
@en
inDataset
type
label
Frequency of all Adverse Event ...... 143a2fea19029cecccec3790efd4e]
@en